Cencora, Inc. (NYSE:COR – Free Report) – Equities researchers at Leerink Partnrs lifted their Q4 2025 earnings per share estimates for shares of Cencora in a note issued to investors on Tuesday, July 1st. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $3.85 for the quarter, up from their previous forecast of $3.84. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Leerink Partnrs also issued estimates for Cencora’s FY2026 earnings at $17.51 EPS, FY2027 earnings at $19.26 EPS and FY2028 earnings at $21.16 EPS.
COR has been the subject of a number of other reports. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Bank of America upped their target price on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Friday, April 11th. Finally, Citigroup raised their price target on Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $306.33.
Cencora Trading Up 1.7%
Shares of COR opened at $296.23 on Wednesday. The stock has a market capitalization of $57.42 billion, a P/E ratio of 34.37, a PEG ratio of 1.44 and a beta of 0.57. Cencora has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The firm has a fifty day simple moving average of $290.91 and a two-hundred day simple moving average of $266.76.
Cencora (NYSE:COR – Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the prior year, the firm posted $3.80 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cornerstone Planning Group LLC grew its stake in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after acquiring an additional 48 shares during the last quarter. Hoey Investments Inc. bought a new position in Cencora in the 1st quarter worth about $28,000. Costello Asset Management INC purchased a new stake in Cencora during the 1st quarter valued at about $28,000. Banque Transatlantique SA bought a new stake in Cencora during the 4th quarter valued at about $29,000. Finally, SBI Securities Co. Ltd. bought a new stake in Cencora during the 4th quarter valued at about $30,000. Institutional investors own 97.52% of the company’s stock.
Insider Transactions at Cencora
In related news, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares in the company, valued at $13,766,900.06. This trade represents a 9.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the firm’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares of the company’s stock, valued at $91,271,982.06. This represents a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,127 shares of company stock worth $9,812,296 over the last ninety days. Insiders own 10.80% of the company’s stock.
Cencora Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Cencora’s dividend payout ratio (DPR) is presently 25.52%.
About Cencora
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
- Five stocks we like better than Cencora
- Earnings Per Share Calculator: How to Calculate EPS
- Rigetti Computing: Cantor’s Bullish Call May Be Just the Start
- Where to Find Earnings Call Transcripts
- Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo Lead
- How to Choose Top Rated Stocks
- 3 Top Stocks Under $20 Riding the “Made in America” Wave
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.